Application 761306
- Type
- BLA
- Sponsor
- ELI LILLY AND CO
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761306 | Ebglyss | lebrikizumab-lbkz | 351(a) | Rx | 2026-09-01 |
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | EBGLYSS | LEBRIKIZUMAB-LBKZ | INJECTABLE;INJECTION | 250MG/2ML | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| EBGLYSS | LEBRIKIZUMAB-LBKZ | Eli Lilly and Company | 7a774ea2-acde-4aaa-9a8f-ccba5a5b1d5f | 2026-06-09 | Warnings, Adverse reactions | BLA761306 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.